Also Clin0 autoimmune conditions; ISB 880 Clin1 autoimmune disease (licensed to Almirall); ISB 1342 Clin1 multiple myeloma, Clin0 T-ALL; ISB 1442 Clin0 multiple myeloma, Clin0 AML; ISB 2001 Clin0 multiple myeloma; ISB 2004 Clin0 hematologic cancers; ISB 2005 Clin0 solid tumors
Ichnos Sciences is developing bispecific and multispecific antibodies called BEAT therapeutics. BEAT therapeutics are designed to simultaneously target multiple disease-causing targets, which can improve the efficacy and safety of treatment. Ichnos Sciences' lead product candidate, ISB 1442, is a bispecific antibody that targets CD38 and CD47. CD38 is a protein that is expressed on cancer cells, while CD47 is a protein that helps cancer cells evade the immune system. ISB 1442 is being developed for the treatment of multiple myeloma. Ichnos Sciences is also developing other BEAT therapeutics for the treatment of cancer, autoimmune diseases, and other diseases.